| Immunotherapy for pancreatic cancer: a 2020 update D Schizas, N Charalampakis, C Kole, P Economopoulou, E Koustas, ... Cancer treatment reviews 86, 102016, 2020 | 354 | 2020 |
| Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome KT Hall, AJ Lembo, I Kirsch, DC Ziogas, J Douaiher, KB Jensen, ... Public Library of Science 7 (10), e48135, 2012 | 259 | 2012 |
| Predicting the outcome of Sjogren’s syndrome-associated non-Hodgkin’s lymphoma patients A Papageorgiou, DC Ziogas, CP Mavragani, E Zintzaras, AG Tzioufas, ... PloS one 10 (2), e0116189, 2015 | 113 | 2015 |
| Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations A Anastasopoulou, DC Ziogas, M Samarkos, JM Kirkwood, H Gogas Journal for immunotherapy of cancer 7, 1-13, 2019 | 111 | 2019 |
| Cardiac and renal complications of carfilzomib in patients with multiple myeloma MA Dimopoulos, M Roussou, M Gavriatopoulou, E Psimenou, D Ziogas, ... Blood Advances 1 (7), 449-454, 2017 | 101 | 2017 |
| Bortezomib‐based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure … MA Dimopoulos, M Roussou, M Gavriatopoulou, E Psimenou, ... American journal of hematology 91 (5), 499-502, 2016 | 101 | 2016 |
| Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma E Kastritis, E Terpos, M Roussou, M Gavriatopoulou, M Migkou, ... Haematologica 102 (3), 593, 2017 | 94 | 2017 |
| Analysis of the quality of reporting of randomized controlled trials in acute and chronic myeloid leukemia, and myelodysplastic syndromes as governed by the CONSORT statement DC Ziogas, E Zintzaras Annals of epidemiology 19 (7), 494-500, 2009 | 72 | 2009 |
| Meta‐analysis: the effects of placebo treatment on gastro‐oesophageal reflux disease F Cremonini, DC Ziogas, HY Chang, E Kokkotou, JM Kelley, L Conboy, ... Alimentary pharmacology & therapeutics 32 (1), 29-42, 2010 | 69 | 2010 |
| Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy E Kastritis, M Gavriatopoulou, M Roussou, M Migkou, D Fotiou, DC Ziogas, ... American Journal of Hematology 92 (7), 632-639, 2017 | 63 | 2017 |
| Oxidative stress and inflammatory markers in the exhaled breath condensate of children with OSA G Malakasioti, E Alexopoulos, C Befani, K Tanou, V Varlami, D Ziogas, ... Sleep and Breathing 16, 703-708, 2012 | 63 | 2012 |
| Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis E Kastritis, I Papassotiriou, G Merlini, P Milani, E Terpos, M Basset, ... Blood, The Journal of the American Society of Hematology 131 (14), 1568-1575, 2018 | 59 | 2018 |
| The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents M Gavriatopoulou, E Kastritis, I Ntanasis-Stathopoulos, D Fotiou, ... Blood, The Journal of the American Society of Hematology 131 (4), 464-467, 2018 | 57 | 2018 |
| Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis E Kastritis, IV Kostopoulos, E Terpos, B Paiva, D Fotiou, M Gavriatopoulou, ... Blood cancer journal 8 (5), 46, 2018 | 51 | 2018 |
| Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit MA Dimopoulos, M Roussou, M Gavriatopoulou, D Fotiou, DC Ziogas, ... Blood cancer journal 7 (6), e571-e571, 2017 | 51 | 2017 |
| A network meta-analysis of randomized controlled trials of induction treatments in acute myeloid leukemia in the elderly DC Ziogas, M Voulgarelis, E Zintzaras Clinical therapeutics 33 (3), 254-279, 2011 | 51 | 2011 |
| MTHFR gene polymorphisms and response to chemotherapy in colorectal cancer: a meta-analysis E Zintzaras, DC Ziogas, GD Kitsios, AA Papathanasiou, J Lau, G Raman Pharmacogenomics 10 (8), 1285-1294, 2009 | 50 | 2009 |
| Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone E Kastritis, I Dialoupi, M Gavriatopoulou, M Roussou, N Kanellias, ... Blood advances 3 (20), 3002-3009, 2019 | 49 | 2019 |
| Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies T Bagratuni, I Ntanasis-Stathopoulos, M Gavriatopoulou, ... Leukemia 32 (12), 2617-2625, 2018 | 46 | 2018 |
| Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib E Kastritis, M Gavriatopoulou, M Roussou, D Fotiou, DC Ziogas, M Migkou, ... Blood cancer journal 7 (6), e570-e570, 2017 | 45 | 2017 |
Meletios Athanasios DimopoulosNational and Kapodistrian University of Athens, School of Medicine在 med.uoa.gr 的电子邮件经过验证
